Want to see UPB full AI Analyst Report?

Upstream Bio, Inc. (UPB) Price & Analysis

266 Followers

UPB Stock Chart & Stats

$30.30

$0.36(1.20%)

At close: Feb 03 4:00 PM EST

$30.30

$0.36(1.20%)

Day’s Range― - ―

52-Week Range$5.85 - $33.68

Previous CloseN/A

Volume30.66K

Average Volume (3M)639.22K

Market Cap

$396.18M

Enterprise Value$239.07M

Total Cash (Recent Filing)$294.58M

Total Debt (Recent Filing)$1.11M

Price to Earnings (P/E)―

Beta1.06

Next Earnings

Aug 12, 2026

EPS Estimate

-0.74

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.91

Shares Outstanding54,419,987

10 Day Avg. Volume754,286

30 Day Avg. Volume639,216

Financial Highlights & Ratios

PEG Ratio-0.13

Price to Book (P/B)4.30

Price to Sales (P/S)512.30

P/FCF Ratio-10.97

Enterprise Value/Market Cap0.60

Enterprise Value/Revenue71.97

Enterprise Value/Gross Profit73.04

Enterprise Value/Ebitda-1.53

Forecast

1Y Price Target

$42.33

Price Target Upside39.71% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-2.87

Revenue Forecast (FY)$2.18M

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetExtremely low leverage gives the company durable financial flexibility to fund clinical programs and survive trial timelines without immediate debt pressure. A strong equity base reduces refinancing risk and preserves strategic optionality for partnerships or milestone financings over months.

Modest Revenue Growth With Solid Gross MarginSustained ~16% TTM revenue growth and a roughly 66% gross margin indicate underlying product candidates or collaborations have favorable cost structure. Over 2–6 months this trend supports improved operating leverage if clinical progress translates to incremental commercialization or partnership revenue.

Governance Continuity And OversightRe-election of directors and auditor ratification provide continuity in board oversight and financial reporting. Stable governance reduces execution and oversight risk, aiding consistent strategic direction and credibility with partners and capital providers during longer clinical development cycles.

Bears Say

High And Worsening Cash BurnSignificant, accelerating cash burn materially shortens runway absent sizable financing or revenue scaling. Over the next several months this structural drain increases dependency on external capital, risking dilution or project delays if funding terms deteriorate or capital markets tighten.

Deep, Persistent Losses And Deteriorating MarginsLarge operating and net losses with deteriorating margins signal the company has yet to convert R&D spending into profitable outputs. Persistently negative returns strain equity value creation and heighten the need for capital, making long-term sustainability contingent on successful trial readouts or licensing.

Clinical-stage Status; No Commercial Product SalesAs a clinical-stage developer without product sales, revenue depends on trial outcomes, partnerships, or milestones. This structural binary risk limits near-term cash generation and makes long-term fundamentals highly contingent on clinical and regulatory progress rather than steady operating cash flows.

Upstream Bio, Inc. News

Upstream Bio management to meet with Piper Sandler

Meeting to be held in New York on June 23 hosted by Piper Sandler. Published first on TheFly...

15d ago

UPB

Upstream Bio presents new responder analyses from VIBRANT trial of verekitug

Upstream Bio (UPB) presented new responder analyses from the Phase 2 VIBRANT trial of verekitug in participants with...

18d ago

UPB

Upstream Bio downgraded to Neutral from Overweight at JPMorgan

JPMorgan downgraded Upstream Bio (UPB) to Neutral from Overweight with a price target of $8, down from $35....

20d ago

UPB

Upstream Bio initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield initiated coverage of Upstream Bio (UPB) with a Buy rating and $36 price...

29d ago

UPB

Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor

An announcement from Upstream Bio, Inc. ( ($UPB) ) is now available. Upstream Bio, Inc. held its 2026...

22d ago

UPB

Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target

Kate Dellorusso, an analyst from LifeSci Capital, maintained the Buy rating on Upstream Bio, Inc.. The associated price...

1M ago

UPB

Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug

Upstream Bio (UPB) presented new data from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic...

1M ago

UPB

Upstream Bio price target lowered to $50 from $51 at Mizuho

Mizuho lowered the firm’s price target on Upstream Bio (UPB) to $50 from $51 and keeps an Outperform...

2M ago

UPB

Yaron Werber Reiterates Buy Rating on Verekitug Developer, Citing Differentiated TSLP Profile, Streamlined Late‑Stage Path, and Cash Runway Through 2027

TD Cowen analyst Yaron Werber has maintained their bullish stance on UPB stock, giving a Buy rating today....

2M ago

UPB

Upstream Bio reports Q1 revenue $1.03M, consensus $347,170

“We continue to make strong progress advancing our clinical programs in severe asthma and CRSwNP to position verekitug...

2M ago

UPB

Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug

Upstream Bio (UPB) announced two upcoming poster presentations at the American Thoracic Society 2026 International Conference in Orlando,...

3M ago

UPB

3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026

High‑risk, high‑reward stocks are not for cautious investors but for those with a big risk appetite. These stocks...

3M ago

UPB

AIOT

Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward

Analyst Kate Dellorusso from LifeSci Capital maintained a Buy rating on Upstream Bio, Inc. and keeping the price...

3M ago

UPB

VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors

Upstream Bio, Inc. ($UPB) announced an update on their ongoing clinical study. Upstream Bio Inc. is running the...

3M ago

UPB

UPB FAQ

What was Upstream Bio, Inc.’s price range in the past 12 months?

Upstream Bio, Inc. lowest stock price was $5.85 and its highest was $33.68 in the past 12 months.

What is Upstream Bio, Inc.’s market cap?

Upstream Bio, Inc.’s market cap is $396.18M.

When is Upstream Bio, Inc.’s upcoming earnings report date?

Upstream Bio, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 41 days.

How were Upstream Bio, Inc.’s earnings last quarter?

Upstream Bio, Inc. released its earnings results on May 13, 2026. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.73 by -$0.02.

Is Upstream Bio, Inc. overvalued?

According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Upstream Bio, Inc. pay dividends?

Upstream Bio, Inc. does not currently pay dividends.

What is Upstream Bio, Inc.’s EPS estimate?

Upstream Bio, Inc.’s EPS estimate is -0.74.

How many shares outstanding does Upstream Bio, Inc. have?

Upstream Bio, Inc. has 54,419,987 shares outstanding.

What happened to Upstream Bio, Inc.’s price movement after its last earnings report?

Upstream Bio, Inc. reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.73. Following the earnings report the stock price went up 4.581%.

Which hedge fund is a major shareholder of Upstream Bio, Inc.?

Currently, no hedge funds are holding shares in UPB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Upstream Bio, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-43.82%

Trailing 12-Months

Asset Growth

-30.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Upstream Bio, Inc.

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

Upstream Bio, Inc. (UPB) Earnings & Revenues

Historic Earnings Reports

UPB Stock 12 Month Forecast

Average Price Target

$42.33

▲(39.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","41":"$41","76":"$76","23.5":"$23.5","58.5":"$58.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.33333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,23.5,41,58.5,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.28,12.489230769230769,17.69846153846154,22.907692307692308,28.11692307692308,33.32615384615385,38.535384615384615,43.744615384615386,48.95384615384616,54.16307692307693,59.3723076923077,64.58153846153846,69.79076923076923,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.28,9.976410256410256,12.672820512820511,15.369230769230768,18.065641025641025,20.76205128205128,23.458461538461535,26.15487179487179,28.85128205128205,31.547692307692305,34.24410256410256,36.940512820512815,39.63692307692307,{"y":42.33333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.28,7.335384615384616,7.390769230769231,7.446153846153846,7.501538461538462,7.556923076923077,7.612307692307692,7.667692307692308,7.723076923076923,7.7784615384615385,7.833846153846154,7.889230769230769,7.944615384615385,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.08,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >